One of the most popular debates in locally advanced head and neck squamous cell carcinoma (LAHNSCC) is the optimal dose and schedule of cisplatin when combined with radical radiotherapy in the curative setting, both postoperatively and as definitive chemoradiotherapy (CRT). Hoping to settle this debate once and for all, we conducted a phase III randomized clinical trial to answer this question (1).
{"title":"Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer","authors":"V. Noronha, V. Patil, A. Joshi, K. Prabhash","doi":"10.21037/tro.2018.12.04","DOIUrl":"https://doi.org/10.21037/tro.2018.12.04","url":null,"abstract":"One of the most popular debates in locally advanced head and neck squamous cell carcinoma (LAHNSCC) is the optimal dose and schedule of cisplatin when combined with radical radiotherapy in the curative setting, both postoperatively and as definitive chemoradiotherapy (CRT). Hoping to settle this debate once and for all, we conducted a phase III randomized clinical trial to answer this question (1).","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42344359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Approximately 20% of patients with colorectal cancer (CRC) are found to have metastatic colorectal cancer (mCRC) at diagnosis, but only 20% of these are usually considered to be potentially resectable (de Haas 2011) (1). Early stage disease in rectal cancer confers a relatively favourable prognosis, but stage IV or metastatic disease is associated with a five-year survival of only 10–15%, despite major advances in multimodality treatment. Individual outcomes are influenced by the site and number of metastases and the specific metastatic sites involved. Patients with rectal primaries are also more likely to present with synchronous lung metastases than patients with colon cancer (Robinson 2018) (2), which then can lead to a different natural history with bone and brain metastases.
{"title":"The role of pelvic radiotherapy in stage IV rectal cancer—still working in the dark!","authors":"R. Glynne-Jones","doi":"10.21037/tro.2018.12.03","DOIUrl":"https://doi.org/10.21037/tro.2018.12.03","url":null,"abstract":"Approximately 20% of patients with colorectal cancer (CRC) are found to have metastatic colorectal cancer (mCRC) at diagnosis, but only 20% of these are usually considered to be potentially resectable (de Haas 2011) (1). Early stage disease in rectal cancer confers a relatively favourable prognosis, but stage IV or metastatic disease is associated with a five-year survival of only 10–15%, despite major advances in multimodality treatment. Individual outcomes are influenced by the site and number of metastases and the specific metastatic sites involved. Patients with rectal primaries are also more likely to present with synchronous lung metastases than patients with colon cancer (Robinson 2018) (2), which then can lead to a different natural history with bone and brain metastases.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46497899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Approximately 10% to 15% of lung cancers are small cell lung cancers (SCLCs). SCLC is divided into two subpopulations—limited-stage (LS) SCLC and extended-stage (ES) SCLC. In LS SCLC, all the lesions are inside the ipsilateral thorax. Lesions beyond this site are categorized as ES SCLC. Prophylactic cranial irradiation (PCI) is considered as the standard of care in patients with LS SCLC who achieve complete response after initial chemotherapy or thoracic radiotherapy. In SCLC, the brain is a common site of distant metastasis.
{"title":"Can prophylactic cranial irradiation of extensive-stage small cell lung cancer prolong survival?","authors":"H. Harada","doi":"10.21037/tro.2018.12.07","DOIUrl":"https://doi.org/10.21037/tro.2018.12.07","url":null,"abstract":"Approximately 10% to 15% of lung cancers are small cell lung cancers (SCLCs). SCLC is divided into two subpopulations—limited-stage (LS) SCLC and extended-stage (ES) SCLC. In LS SCLC, all the lesions are inside the ipsilateral thorax. Lesions beyond this site are categorized as ES SCLC. Prophylactic cranial irradiation (PCI) is considered as the standard of care in patients with LS SCLC who achieve complete response after initial chemotherapy or thoracic radiotherapy. In SCLC, the brain is a common site of distant metastasis.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45847489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We thank van Rhoon and van Holthe for their interests and comments on our article of combined hyperthermia (HT) and radiation therapy (RT) for painful bony metastases (1). In our study, a significant pain improvement and duration of response was demonstrated by HT + RT. We emphasized the complete response (CR) rate at the third month than the accumulated CR rate within 3 months, because the palliative goal for the good performance patients should focus more on long-lasting response (2). Our analysis was indeed limited by small patient size (58 patients). However, timing of preset analysis and the rule of early termination were performed according to protocol and were mandated by the institutional review board and health regulatory authorities for clinical trials.
{"title":"Radiotherapy plus hyperthermia is effective for painful bony metastases—optimal schedule unsettled","authors":"M. Chi, Kai-Lin Yang, K. Chi","doi":"10.21037/tro.2018.12.02","DOIUrl":"https://doi.org/10.21037/tro.2018.12.02","url":null,"abstract":"We thank van Rhoon and van Holthe for their interests and comments on our article of combined hyperthermia (HT) and radiation therapy (RT) for painful bony metastases (1). In our study, a significant pain improvement and duration of response was demonstrated by HT + RT. We emphasized the complete response (CR) rate at the third month than the accumulated CR rate within 3 months, because the palliative goal for the good performance patients should focus more on long-lasting response (2). Our analysis was indeed limited by small patient size (58 patients). However, timing of preset analysis and the rule of early termination were performed according to protocol and were mandated by the institutional review board and health regulatory authorities for clinical trials.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43593535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A beam shaping assembly (BSA), a neutron moderator system, is a key component of an accelerator based boron neutron capture therapy (BNCT) facility. The neutron energy recommended in the IAEA TECDOC-1223 for the BNCT is much lower than the energy of the neutrons produced by accelerator induced nuclear reactions. The neutron energy depends on the energy of the incident particle and nuclear reaction. Therefore, the BSA should be designed considering the neutron energy dependency. Now, several kinds of accelerators and reactions are used and proposed. Here, neutron producing reaction, moderator system, and activations are introduced.
{"title":"Accelerator-based neutron source for boron neutron capture therapy","authors":"Y. Kiyanagi","doi":"10.21037/TRO.2018.10.05","DOIUrl":"https://doi.org/10.21037/TRO.2018.10.05","url":null,"abstract":"A beam shaping assembly (BSA), a neutron moderator system, is a key component of an accelerator based boron neutron capture therapy (BNCT) facility. The neutron energy recommended in the IAEA TECDOC-1223 for the BNCT is much lower than the energy of the neutrons produced by accelerator induced nuclear reactions. The neutron energy depends on the energy of the incident particle and nuclear reaction. Therefore, the BSA should be designed considering the neutron energy dependency. Now, several kinds of accelerators and reactions are used and proposed. Here, neutron producing reaction, moderator system, and activations are introduced.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2018.10.05","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48408669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The 18th International Congress on Neutron Capture Therapy was held successfully for the first time in Taipei, Taiwan from October 28 through November 2, 2018. The congress was spread over six days and featured training courses, parallel sessions, plenary talks, invited lectures, and poster viewing and presentations.
{"title":"Dr. Tatsuhiko Sato: a new model for estimating therapeutic effect of BNCT using the PHITS code","authors":"Te-Chi Lin","doi":"10.21037/tro.2018.11.02","DOIUrl":"https://doi.org/10.21037/tro.2018.11.02","url":null,"abstract":"The 18th International Congress on Neutron Capture Therapy was held successfully for the first time in Taipei, Taiwan from October 28 through November 2, 2018. The congress was spread over six days and featured training courses, parallel sessions, plenary talks, invited lectures, and poster viewing and presentations.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43472388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The 18 th International Congress on Neutron Capture Therapy was held successfully for the first time in Taipei, Taiwan from October 28 through November 2, 2018. The congress was spread over six days and featured training courses, parallel sessions, plenary talks, invited lectures, and poster viewing and presentations.
{"title":"Dr. Amanda E. Schwint: enjoy every step of the way and admit “there are always more questions than answers”","authors":"Te-Chi Lin","doi":"10.21037/TRO.2018.12.01","DOIUrl":"https://doi.org/10.21037/TRO.2018.12.01","url":null,"abstract":"The 18 th International Congress on Neutron Capture Therapy was held successfully for the first time in Taipei, Taiwan from October 28 through November 2, 2018. The congress was spread over six days and featured training courses, parallel sessions, plenary talks, invited lectures, and poster viewing and presentations.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47831258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The 18 th International Congress on Neutron Capture Therapy was held successfully at theChang Yung-Fa International Convention Center in Taipei, Taiwan from October 28 th to November 2 nd , 2018. The theme of the 18 th Congress is“Precision Therapy, Beautiful Tomorrow—We Here, We Care.” This congressgathered international clinicians and researchers from academia and industry toshare their findings and generate new thoughts and discoveries related to boronneutron capture therapy (BNCT). The key areas included recent clinical results,the latest development in accelerator-based neutron sources, the nextgeneration of boron-10 delivery agents, as well as progress in chemical and biologicalresearch.
{"title":"Prof. Rolf F. Barth: the future of boron neutron capture therapy will depend on the clinical trials of accelerator-based boron neutron capture therapy","authors":"Tan-Lun Yu","doi":"10.21037/tro.2018.11.03","DOIUrl":"https://doi.org/10.21037/tro.2018.11.03","url":null,"abstract":"The 18 th International Congress on Neutron Capture Therapy was held successfully at theChang Yung-Fa International Convention Center in Taipei, Taiwan from October 28 th to November 2 nd , 2018. The theme of the 18 th Congress is“Precision Therapy, Beautiful Tomorrow—We Here, We Care.” This congressgathered international clinicians and researchers from academia and industry toshare their findings and generate new thoughts and discoveries related to boronneutron capture therapy (BNCT). The key areas included recent clinical results,the latest development in accelerator-based neutron sources, the nextgeneration of boron-10 delivery agents, as well as progress in chemical and biologicalresearch.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tro.2018.11.03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43696269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Boron neutron capture therapy (BNCT) is one of the hopeful cancer therapies. Until recently, BNCT used the Nuclear fission reactor as a neutron source. However, many usable reactors for BNCT have been terminated and it is hard recently to build the new research reactor in many countries. Thus, a small accelerator which can supply the intense proton beam become a candidate of a neutron source instead of the reactor. Furthermore, it is impossible to install the reactor in a hospital but we can install the accelerator system in the hospital. In this article we describe the basic physics of the linear accelerator and cyclotron for BNCT. An ion source and the target for neutron production are also described briefly.
{"title":"Introduction to accelerators for boron neutron capture therapy","authors":"F. Naito","doi":"10.21037/tro.2018.10.11","DOIUrl":"https://doi.org/10.21037/tro.2018.10.11","url":null,"abstract":"Boron neutron capture therapy (BNCT) is one of the hopeful cancer therapies. Until recently, BNCT used the Nuclear fission reactor as a neutron source. However, many usable reactors for BNCT have been terminated and it is hard recently to build the new research reactor in many countries. Thus, a small accelerator which can supply the intense proton beam become a candidate of a neutron source instead of the reactor. Furthermore, it is impossible to install the reactor in a hospital but we can install the accelerator system in the hospital. In this article we describe the basic physics of the linear accelerator and cyclotron for BNCT. An ion source and the target for neutron production are also described briefly.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tro.2018.10.11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46421889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast conservative surgery followed by radiotherapy has been increasingly used for treating breast cancer, particularly for those with early stage disease to allow organ preservation while maintaining similar oncological outcomes when compared to mastectomy (1,2). Traditional radiotherapy in such settings includes treating the whole breast in conventional fractionation of 2 Gray (Gy) per fraction to total 25 fractions over 5 weeks, with or without boost to the tumor bed to further decrease local recurrence (3,4).
{"title":"Can the dermatitis from the hot spot be minimised by barrier film?","authors":"F. Lim, B. A. Wan, Y. Razvi, E. Chow","doi":"10.21037/TRO.2018.10.07","DOIUrl":"https://doi.org/10.21037/TRO.2018.10.07","url":null,"abstract":"Breast conservative surgery followed by radiotherapy has been increasingly used for treating breast cancer, particularly for those with early stage disease to allow organ preservation while maintaining similar oncological outcomes when compared to mastectomy (1,2). Traditional radiotherapy in such settings includes treating the whole breast in conventional fractionation of 2 Gray (Gy) per fraction to total 25 fractions over 5 weeks, with or without boost to the tumor bed to further decrease local recurrence (3,4).","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2018.10.07","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48577388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：